The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Significant CLL trial updates to come at ASH 2020
John Gribben, MD, DSc, FRCP, FRCPath, FMed Sci, Barts Cancer Institute, London, UK shares what important chronic lymphocytic leukemia (CLL) trial updates will be coming up at ASH 2020. A number of studies focused on combined ibrutinib plus venetoclax therapy will share results, including the US-based Phase II CAPTIVATE study. He also looks forward to seeing the 5-year MURANO study updates of venetoclax-rituximab in relapsed/refractory CLL, and further data on BTK inhibitors, such as LOXO-305. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
